Buying pressure lifts Injective higher in today trading

Traders Union
All News
Crypto News
Injective surges 10.06% today to $3.59

Highlights

Injective's IIP-619 mainnet upgrade proposal passed with 99.99% staked support, targeting MultiVM EVM expansion, improved scalability, Chainlink integration, and shared liquidity.
Institutional sentiment rose as Pineapple Financial accumulated over 7 million INJ tokens and committed $2 million to the Injective ecosystem.
INJ trades at $3.59 above its MA-20 of $3.24, but with bearish medium/long-term trend; resistance at $3.60, support at $2.66–$2.82, and low probability of price breakout.

Governance upgrade and institutional buying lift market sentiment

Injective approved the IIP-619 mainnet upgrade proposal, aiming to expand its MultiVM Ethereum Virtual Machine architecture, enhance scalability, deepen Chainlink oracle integration, and improve shared liquidity. The governance vote saw nearly unanimous support at 99.99% of staked participation. Institutional activity increased as Pineapple Financial accumulated over 7 million INJ tokens and invested $2 million into the Injective ecosystem, further supporting market sentiment.

Anton Kharitonov, expert at Traders Union, views the recent Injective surge as fragile. He notes that price remains below dominant moving averages, signaling weak longer-term structure and unresolved seller pressure. Despite the positive market reaction to institutional accumulation and the IIP-619 vote, Kharitonov highlights persistent bearish technicals, mixed momentum, and gap risks. He sees limited upside due to the strong resistance at $3.60 and underlines the forecast for a likely decline. "Until Injective demonstrates a convincing move above $3.60 and the daily bearish signals reverse, I see little reason for optimism here."

Viktoras Karapetjanc, expert at Traders Union, believes Injective’s ecosystem is strengthening. He points to the decisive governance support and significant institutional investments as key bullish signals for long-term growth. Karapetjanc sees the upgrade and enhanced Chainlink integration adding utility and attracting further capital. "The bullish structure remains intact — with this level of institutional faith and ecosystem progress, I expect further growth once volatility settles."

Jainam Mehta, market strategist, observes that Injective’s near-term rally faces notable resistance near $3.60. Mehta notes sideways technicals and the overbought condition flagged by the Stoch RSI, suggesting bulls may lose momentum. He hints at possible tactical opportunities for nimble traders if a breakout or support test occurs. "If price fails to clear $3.60 and momentum weakens, I would watch for contrarian entries closer to the $2.74 zone."

Mixed momentum signals amid resistance at dynamic kijun level

According to Ichimoku analysis, the kijun level near $3.60 acts as a dynamic resistance, while the MA-20 zone around $3.24 provides short-term support. Momentum signals are mixed; the daily MACD and ADX indicate strong bearish momentum, yet the Stoch RSI is in overbought territory and daily RSI registers around 47, implying that INJ is not oversold but may be nearing exhaustion after today's rally. BBP strongly favors buyers and intraday action has been bullish, although the Awesome Oscillator and CCI remain neutral. Today's session opened with a gap up from $3.26 to $3.44 and has sustained strength to the session highs on high volatility.

Previously it was reported that Injective is showing short-term bullish momentum above the 20-day moving average but remains constrained by persistent medium- and long-term selling pressure, with technical indicators such as MACD, ADX, and RSI signaling ongoing bearish trends and overbought intraday conditions. Immediate resistance is identified near $3.60–$3.61, while failure to break higher could result in consolidation or a retest of support around $3.20.

Source of Data: INJ Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.